DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves midday: GameStop, Viking Therapeutics, Trump Media and more
▼ + stars: | 2024-09-11 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Trump Media & Technology — The stock fell more than 13% following Tuesday's debate between majority shareholder former President Donald Trump and Democratic Vice President Kamala Harris. Novartis — U.S.-listed shares of the Swiss pharma company slipped nearly 2% on the heels of Bank of America's downgrade to hold from buy. Crypto stocks — Crypto stocks were dragged downward after the price of bitcoin fell slightly overnight, as crypto traders considered central bank policy in Japan . Morgan Stanley — The bank stock lost 1% following a downgrade at Goldman Sachs to neutral from buy. Solar stocks — Solar stocks rose as a group after Vice President Kamala Harris's performance at Tuesday's debate raised confidence in a Democratic victory at the U.S. presidential election.

Persons: Donald Trump, Kamala Harris, Rentokil, it's, bitcoin, Morgan Stanley, Goldman Sachs, Goldman, Morgan, Warren Buffett's Berkshire Hathaway, Kamala Harris's, — CNBC's Sean Conlon, Michelle Fox, Alex Harring, Yun Li, Sarah Min, Samantha Subin Organizations: Trump Media & Technology, Democratic, Trump Media, Nasdaq, GameStop, Novartis — U.S, Swiss pharma, of, Therapeutics, JPMorgan, Viking Therapeutics, Goldman, Bank of America, U.S, Clean Energy, SolarEdge Technology, Sunnova Energy Locations: North America, Japan

☆ JPMorgan says this new player in the GLP-1 market could rally 45%
▼ + stars: | 2024-09-11 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

JPMorgan thinks Viking Therapeutics could be the next big name in the GLP-1 boom. Investors are awaiting more details about the oral version, expected in early November, as a possible catalyst for the stock. VKTX YTD mountain Viking Therapeutics stock. Some patients who take these popular obesity drugs suffer nausea and gastrointensinal effects that force them to stop treatment. Oral drugs also tend to be cheaper and easier to manufacture.

Persons: GLP, Eli Lilly, Viking, Hardik Parikh, Parikh, Wegovy, Eli Lilly's Zepbound Organizations: JPMorgan, Viking, Therapeutics, Novo Nordisk, Investors, Viking Therapeutics

☆ Here are Wednesday's biggest analyst calls: Nvidia, Apple, Spotify, Arm, Robinhood, Alphabet, Shopify, Disney & more
▼ + stars: | 2024-09-11 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Wednesday's biggest calls on Wall Street: Goldman Sachs downgrades Morgan Stanley to neutral from buy Goldman said it sees better value elsewhere than Morgan Stanley. Goldman Sachs upgrades Evercore to buy from neutral Goldman said the investment banking firm is "best in class." JPMorgan reiterates Nvidia as overweight JPMorgan said stocks such as Nvidia are "strong beneficiaries in the emerging AI arms race." Morgan Stanley reiterates Arm as a top pick Morgan Stanley said it's sticking with its overweight rating on the semiconductor chip company. Bank of America reiterates Apple as buy Bank of America said it's standing by its buy rating on shares of Apple.

Persons: Goldman Sachs downgrades Morgan Stanley, Goldman, Morgan Stanley, Goldman Sachs, Rosenblatt, Canaan, Jefferies, Williams, Guggenheim, it's, orals, it's bullish, Bernstein, Robinhood, Wells, Shopify, Truist, Wolfe Organizations: NASDAQ, JPMorgan, Viking Therapeutics, Citi, Apollo Global Citi, APO, U.S, " Bank of America, Novartis, Bank of America, Nvidia, Apple, Spotify, Disney, AES, ~$ Locations: Canaan, Williams, Sonoma, 2030E

☆ Stocks making the biggest moves premarket: Trump Media, GameStop, Dave & Buster's and more
▼ + stars: | 2024-09-11 | by ( Sean Conlon | ) www.cnbc.com time to read: +2 min

Trump Media & Technology – Shares slid more than 11% in the wake of the debate between Republican nominee Donald Trump and Democratic Vice President Kamala Harris . Dave & Buster's – The entertainment stock popped more than 13% after topping earnings estimates for the recent quarter by 15 cents a share. GameStop – The video game retailer's shares plunged more than 10% in premarket trading after the company reported a steep decline in sales. GameStop also announced an "at-the-market" stock offering of up to 20 million shares. Morgan Stanley – Shares of the major bank were down more than 1% after Goldman Sachs downgraded the stock to neutral from buy.

Persons: Donald Trump, Kamala Harris, Rentokil, Rollins, Dave, Buster's, Jefferies, Stocks, Coinbase, MicroStrategy, MARA, Morgan Stanley –, Goldman Sachs, Goldman, Morgan Stanley, —, Alex Harring, Samantha Subin, Jesse Pound, Yun Li, Sarah Min, Tanaya Macheel, Michelle Fox Organizations: Trump Media & Technology, Republican, Democratic, Trump Media, GameStop, Williams, Sonoma, Jefferies, Novartis – U.S, Bank of America, Novartis, Viking Therapeutics, JPMorgan, MARA Holdings Locations: North America, Swiss, Japan

The rate of weight loss with the experimental pill, called amycretin, appears to be more rapid than what’s seen for other drugs. “It’s roughly double the weight loss rate seen with current GLP-1 agonists and approaching procedural or surgical-level outcomes,” said Dr. Christopher McGowan, a gastroenterologist who runs a weight loss clinic in North Carolina. McGowan said that while the weight loss was significant, he still has concerns about how fast people lost weight. “While losing weight is seemingly the end goal, how that weight is lost matters,” he said. Spratt said she would like to know how much of the weight loss came from fat compared with muscle.

Persons: “, ”, Christopher McGowan, ” Dr, Susan Spratt, Spratt, haven’t, Martin Lange, Lange, McGowan, ” McGowan Organizations: Novo Nordisk, European Association for, Diabetes, Population Health Management, Duke Health Locations: Novo, Spain, North Carolina, semaglutide, Wegovy, It’s

The findings bring the phenomenon — and the controversy — of the latest new and powerful weight loss drugs to the youngest age group yet. The new trial looked at liraglutide, the active ingredient used in two of Novo Nordisk’s older GLP-1 drugs: Saxenda, a weight loss drug, and Victoza, a diabetes drug. So instead of looking at overall weight loss like in adult studies, they decided to focus more on BMI, which takes into account both weight and height. A spokesperson for Novo Nordisk said that it has submitted an application to the Food and Drug Administration to expand the approval of liraglutide for weight loss in children ages 6 to 11. Is 6 too young for a weight loss drug?

Persons: Roy Kim, “, ” Kim, Claudia Fox, Fox, Eli Lilly, ”, liraglutide, ” Fox, Sarah Armstrong, ” Armstrong, comorbidities, it’s, ” Wegovy, Zepbound, Shauna Levy, ” Levy Organizations: New England, of Medicine, Novo Nordisk, Cleveland Clinic, Centers for Disease Control, University of Minnesota, BMI, Food and Drug Administration, American Academy of Pediatrics, Duke University, Tulane Bariatric Center Locations: liraglutide, Ozempic, Ohio, U.S, New Orleans

☆ Mondelez is trading as if GLP-1 drugs don't exist, says Jim Cramer
▼ + stars: | 2024-09-10 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMondelez is trading as if GLP-1 drugs don't exist, says Jim Cramer'Mad Money' host Jim Cramer looks at how Mondelez is dealing with GLP-1 drugs.

Persons: Jim Cramer

☆ Wall Street embraced food plays as recession-proof stocks, says Jim Cramer
▼ + stars: | 2024-09-10 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWall Street embraced food plays as recession-proof stocks, says Jim Cramer'Mad Money' host Jim Cramer looks at how Mondelez is dealing with GLP-1 drugs.

Persons: Jim Cramer

☆ After Mondelez's gains, Cramer says wait to buy stock until the Fed cuts interest rates
▼ + stars: | 2024-09-10 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

"But, longer term, a well-run snack food company is a great place to be." Mondelez stock jumped over the past few weeks, now up more than 4% since the beginning of September, according to FactSet. To Cramer, Wall Street has embraced recession-proof food companies like Mondelez as investors worry about an economic slowdown. Lower rates makes these stocks "go out of style in the Wall Street fashion show," he added. He also expressed concerns about the effect of GLP-1 weight loss drugs on snack food companies as a whole.

Persons: CNBC's Jim Cramer, Cramer, Wall, Dirk Van de, Mondelez, Van de Organizations: Federal Reserve, Mondelez, Cadbury, Ritz, Fed, Bloomberg Locations: Mondelez

The direct-to-consumer health-care startup Ro launched a new free tool Tuesday to help patients determine whether their insurance covers a buzzy class of weight loss and diabetes drugs called GLP-1s. Ro said nearly half of the company's patients have some form of insurance coverage for a GLP-1, according to its customer data. Ro said it hopes its new tool can help patients understand their coverage options so they can decide how to pursue weight loss. The digital health company may benefit too, as it could drive some patients to join the company's GLP-1 program. It includes 24/7 messaging, one-on-one coaching with nurses and help with navigating insurance coverage.

Persons: Ro, Zachariah Reitano Organizations: Novo Nordisk, CNBC Locations: U.S

☆ Ro CEO talks new GLP-1 insurance coverage tool
▼ + stars: | 2024-08-13 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRo CEO talks new GLP-1 insurance coverage toolZach Reitano, Ro CEO, joins 'Fast Money' to talk the companies new GLP-1 insurance tool.

Persons: Zach Reitano

☆ Cramer points out current economic issues some companies are ignoring
▼ + stars: | 2024-08-12 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Monday said a variety of companies, to their detriment, won't admit they're hurting due to certain ongoing economic trends. "If they'd just own up, I think they'd earn a lot of credibility for themselves, leading to higher stock prices down the line. Cramer pointed to Jack Daniels maker Brown-Forman , which missed estimates during its most recent quarter and is down about 23% year to date. Cramer also mentioned peer spirit company Diageo , which saw sales decline in its most recent quarter and is down more than 14% year to date. According to Cramer, few companies have lowered prices since they raised them during the Covid-19 pandemic.

Persons: CNBC's Jim Cramer, Cramer, Jack Daniels, Brown, Forman, they'll Organizations: Diageo, Costco, Walmart, Enterprise

☆ Deutsche Bank says Eli Lilly stock is a buy — in line with our rating on shares
▼ + stars: | 2024-08-12 | by ( Morgan Chittum | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Deutsche Bank upgraded Eli Lilly to a buy from hold rating on Monday after a blowout quarterly earnings report last week. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, We've, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Dow Jones, Federal, The Club, Management, Amazon Web Services, Deutsche Bank, Novo Nordisk

☆ Blink Fitness files for bankruptcy and may close some gyms
▼ + stars: | 2024-08-12 | by ( Nathaniel Meyersohn | ) edition.cnn.com time to read: +1 min

Blink Fitness, the low-price gym chain with monthly memberships ranging from $15 to $45, filed for bankruptcy Monday and said it may close an unspecified number of its 101 clubs. Several major chains, including 24 Hour Fitness and Gold’s Gym, filed for bankruptcy. Blink’s bankruptcy shows the lingering impact of the pandemic on the fitness industry. “It’s a sign that this is an industry still going through growing pains post-Covid,” Rick Caro, the president of fitness industry consulting firm Management Vision, told CNN. The fitness industry faces other challenges, such as consumers cutting back on discretionary spending and the rise of GLP-1 drugs used for weight loss.

Persons: Blink, ” Rick Caro Organizations: New, New York CNN, Health & Fitness Association, Management Vision, CNN Locations: New York, New York , New Jersey , California, Texas

☆ No food or beverage company will admit GLP-1s hurt them at all, says Jim Cramer
▼ + stars: | 2024-08-12 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNo food or beverage company will admit GLP-1s hurt them at all, says Jim Cramer'Mad Money' host Jim Cramer looks at the topics companies are avoiding right now.

Persons: Jim Cramer

☆ A man lost 100 pounds and kept them off by making two simple lifestyle changes
▼ + stars: | 2024-08-08 | by ( Kim Schewitz | ) www.businessinsider.com time to read: +7 min

"I lost weight, but it wasn't in the healthiest way. AdvertisementXavier lost 100 pounds in high school on a restrictive diet, but it was "unsustainable," he said. Benji Xavier lost 100 pounds by making healthier versions of his favorite foods at home. AdvertisementXavier has maintained his weight loss by making healthy lifestyle changes. He has "cheat days," and eats whatever he wants on holiday without feeling guilty because he knows he'll return home to a healthy lifestyle.

Persons: —, Benji Xavier, Xavier, He's, unconfident, It's, he'll, it's, I'm Organizations: Service, Business, Centers for Disease Control, CDC Locations: New Jersey

☆ Eli Lilly's second quarter eases Zepbound pricing fears and suggests it's making headway in weight loss race
▼ + stars: | 2024-08-08 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Lilly's shares are up more than 7% on the news. LLY YTD mountain Eli Lilly shares year to date. The first followed positive reports from rivals that showed they were making progress in developing their own weight loss drugs . However, sales rose 59% for Mounjaro quarter over quarter and were up 140% for Zepbound as Lilly saw better pricing. Meanwhile, analysts see several events on the horizon that could further boost Lilly's shares in coming months.

Persons: Eli Lilly, Bansal, Lilly, Carter Gould, Lilly's headwinds, Novo's, Wells Fargo's Bansal, Evan David Seigerman, Chris Schott, Schott, Lilly's Organizations: Novo Nordisk, Wells, Barclays, Nordisk, BMO Capital Markets, Food and Drug Administration Locations: Wells Fargo, Lilly's, Wednesday's

☆ Eli Lilly's blowout quarter should quiet investor concerns about the stock
▼ + stars: | 2024-08-08 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. The report left little doubt that Eli Lilly's best days are ahead, driven by the growth of GLP-1s. It's really early" for Zepbound, Eli Lilly CEO David Ricks said in a CNBC interview Thursday. But the good news is Eli Lilly's multibillion dollar investments to expand manufacturing capacity are paying off.

Persons: Eli Lilly, Eli Lilly's, Zepbound, Jim Cramer, Lilly, David Ricks, It's, We're, Eli Lilly hasn't, Novo, spooked Lilly, Gordon Brooks, it's, Ricks, Brooks, Verzenio, —, didn't, Jim Cramer's, Jim, George Frey Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, CNBC, Food and Drug Administration, Viking Therapeutics, Novo Nordisk —, FDA, RTP, Bloomberg, Getty Locations: Eisai, U.S, GLP, Roche, it's, Indianapolis, North Carolina, Europe, Germany, Provo , Utah

☆ Here's why Eli Lilly is down heading into earnings — and how we plan to play it
▼ + stars: | 2024-08-07 | by ( Morgan Chittum | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Eli Lilly shares declined 1.7% Wednesday after peer Novo Nordisk posted disappointing earnings results before the bell. Investors are weighing if the same fate is in store for Club holding Eli Lilly and its GLP-1 drugs Zepbound and Mounjaro. Still, Jim said Eli Lilly shares could fall further after the drugmaker releases its own quarterly results on Thursday. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Dow, Eli Lilly, —, Jim, That's, Jim Cramer's Organizations: CNBC, Dow Jones Industrial, Nasdaq, Novo Nordisk, Club, Novo Nordisk's, CVS, Management

☆ A man rapidly lost weight on a popular weight-loss drug. After 6 months, he was hospitalized with heart problems and confusion.
▼ + stars: | 2024-08-07 | by ( ) www.businessinsider.com time to read: +4 min

Read previewSix months after he started taking a weight-loss drug, a 62-year-old man was hospitalized with heart palpitations, tremors, confusion, fever, and sweating. The man, from Colorado, had been prescribed the drug tirzepatide (the active ingredient in Mounjaro and Zepbound) to lose weight. Over time, the patient decreased his insulin dose as he lost weight, but didn't change his thyroid medication. This highlights the potential risks of losing weight too quickly, and the need for medical supervision while using the drugs, they said. AdvertisementOzempic and Wegovy, brand names for semaglutide showed weight loss of about 15% over a similar time period.

Persons: —, Barbara Davis, they've Organizations: Service, Business, Barbara, Barbara Davis Center, Diabetes, University of Colorado, FDA Locations: Colorado

☆ Eli Lilly reports earnings Thursday. Here's what Wall Street is watching
▼ + stars: | 2024-08-07 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Novo Nordisk shocked investors on Wednesday when its latest results fell short of Wall Street's expectations. While Eli Lilly's stock remains up about 32% year to date, concerns about increasing competition in the category have resulted in a nearly 16% decline for Lilly shares over the past month. Eli Lilly is making similar attempts with Zepbound, but its launch is at an earlier stage than Wegovy. Second-quarter sales of Ozempic, Novo's diabetes treatment, rose 4% from the first quarter, while Wegovy revenue grew 24% quarter over quarter. Barclays analyst Emily Field told clients in a research note that she would be a buyer of Novo Nordisk shares on the weakness.

Persons: Eli Lilly, Eli, Lilly, Wells, Mohit Bansal, Ozempic, Bansal, Emily Field, David Song, Song, Chris Schott, Schott Organizations: Novo Nordisk, LSEG, Lilly's, Management, Food and Drug Administration, Barclays, Tema, JPMorgan Locations: Wells Fargo, IQVIA, Amgen, MariTide, Novo, CagriSema

☆ The stock market is in no man's land. Here's what investors should expect next
▼ + stars: | 2024-08-04 | by ( Jim Cramer | ) www.cnbc.com time to read: +16 min

Anything above 4% indicates the market is overbought, anything below a minus 5% means the market is oversold.) I am just prematurely predicting other investors fleeing the stock because they think Warren knows more than them. Many investors thought that Amazon was the best set up of the Mag Seven going into earnings. We are right smack in a most perilous moment because the Fed doesn't want to move too fast but the stock market does and the Fed does not care about that. I don't think a presidential election is all that conducive to the market.

Persons: Warren Buffett's Berkshire Hathaway, Apple, Warren, That's, Buffett, Tim Cook, Cook, Carl Icahn, I'd, Donald Trump, don't, Jerome Powell, Meta, It's, Pat Gelsinger, Andy Grove, Gelsinger, Craig Barrett, that's, Pat, Let's, Mark Zuckerberg, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Dow, of America, Apple, Microsoft, Bank of America, Amazon Web Services, Investors, Comcast, Walgreens, CVS, Federal, whimpers, Amazon, Nvidia, Meta, Intel, Lenovo, Dell, HP, CNBC, Jim Cramer's Charitable, Traders, New York Stock Exchange Locations: Friday's, China, —, Wells, U.S, humorless, Taiwan, Brookfield, Arizona, NBCUniversal

☆ Nearly half of online pharmacies selling weight loss drugs are operating illegally, study finds
▼ + stars: | 2024-08-02 | by ( Liz Szabo | Liz Szabo Is An Independent Health | Science Journalist. Her Work Has Won Multiple National Awards. One Of Her Investigations Led To A New State Law In Virginia. | ) www.nbcnews.com time to read: +8 min

Consumers who try to buy popular weight loss drugs online without a prescription risk being scammed or receiving unsafe products, a new study shows. Shortages of the popular weight loss medication, which belongs to a class of drugs called GLP-1s, have led to “a black market of illegal knockoffs,” said Dr. Christopher McGowan, the founder, medical director and research director of True You Weight Loss, a weight loss clinic in Cary, North Carolina. Medicare doesn’t cover the drugs when prescribed for weight loss, and many state Medicaid plans heavily restrict coverage. Online scamsSome websites purporting to be online pharmacies take consumers’ money but never deliver the medications, according to the study. Consumers won’t get that sort of care if they buy drugs online without seeing a health care provider.

Persons: ”, Tim Mackey, Christopher McGowan, McGowan, semaglutide, won’t, Mackey, ” McGowan, “, Shabbir Safdar, Scott Brunner, Safdar, Brunner, Consumers won’t, it’s Organizations: Nordisk’s, University of California, Global Health, Data Institute, University of Pecs, FDA, Manufacturers can’t, Medicare, JAMA, Food and Drug Administration, semaglutide, Novo Nordisk, telltale, Partnership, Safe Medicines, Alliance, Pharmacy, Consumers Locations: San Diego, Hungary, Cary , North Carolina, U.S

Jim Cramer said Friday the Fed should have cut at this week's meeting. Those were in place with AMD because Jim Cramer mentioned the stock on CNBC TV over the past 72 hours. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Dow Jones, here's, Eli Lilly, Jim Cramer's, Jim Organizations: CNBC, Dow Jones, Nasdaq, Federal Reserve, Fed, Bond, chipmaker Broadcom, AMD, Palo Alto, Nvidia, Wynn Resorts, Disney, Jim Cramer's Charitable Locations: U.S, DuPont, Dover, Wells

☆ Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage study
▼ + stars: | 2024-08-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Eli Lilly 's weight loss drug Zepbound showed benefits in patients with a common type of heart failure and obesity, according to late-stage trial data the company released Thursday. Eli Lilly said it plans to submit the results from the phase three trial to regulators in the U.S. and other agencies starting later this year. Zepbound also significantly improved heart failure symptoms and physical limitations, Eli Lilly said in a release. Eli Lilly will present the data at an upcoming medical meeting and submit it to a peer-reviewed journal.

Persons: Eli Lilly, Zepbound Organizations: Centers for Disease Control, Novo Nordisk, Drug Administration Locations: Brooklyn, New York, U.S

Search resuls for: "GLP"

25 mentions found